Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
12.70
-0.71 (-5.29%)
At close: Mar 13, 2026, 4:00 PM EDT
12.53
-0.17 (-1.34%)
After-hours: Mar 13, 2026, 5:51 PM EDT
Enanta Pharmaceuticals Employees
Enanta Pharmaceuticals had 120 employees as of September 30, 2025. The number of employees decreased by 11 or -8.40% compared to the previous year.
Employees
120
Change (1Y)
-11
Growth (1Y)
-8.40%
Revenue / Employee
$558,167
Profits / Employee
-$596,142
Market Cap
368.55M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 120 | -11 | -8.40% |
| Sep 30, 2024 | 131 | -14 | -9.66% |
| Sep 30, 2023 | 145 | -15 | -9.38% |
| Sep 30, 2022 | 160 | 5 | 3.23% |
| Sep 30, 2021 | 155 | 14 | 9.93% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 650 |
| Ginkgo Bioworks Holdings | 485 |
| Sutro Biopharma | 178 |
| Lineage Cell Therapeutics | 77 |
| Armata Pharmaceuticals | 60 |
| PureTech Health | 56 |
| Shattuck Labs | 44 |
| DiaMedica Therapeutics | 28 |
ENTA News
- 11 days ago - Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference - Business Wire
- 4 weeks ago - Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting - Business Wire
- 4 weeks ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 - Business Wire
- 2 months ago - Enanta Pharmaceuticals, Inc. (ENTA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook - Business Wire
- 2 months ago - Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 4 months ago - Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development - Seeking Alpha
- 4 months ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025 - Business Wire